Sign In  |  Register  |  About Los Altos  |  Contact Us

Los Altos, CA
September 01, 2020 1:26pm
7-Day Forecast | Traffic

  • Search Hotels in Los Altos

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AbbVie (NY: ABBV )

180.78 -2.15 (-1.17%)
Streaming Delayed Price Updated: 11:40 AM EST, Dec 2, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AbbVie

< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
71 72 Next >
3 Reasons to Buy AbbVie Stock on the Dip
A little patience with the drugmaker should pay off. 
Via The Motley Fool
MarketBeat Week in Review – 4/29 - 5/3
Apple, Amgen, and a weak jobs report helped move the market higher as investors temporarily looked past the possibility of no interest rate cuts in 2024 
Via MarketBeat
Topics Economy Stocks
Exposures Interest Rates US Equities
$1000 Invested In This Stock 10 Years Ago Would Be Worth $3,100 Today
Via Benzinga
7 Safe Haven Stocks That Can Withstand the Market’s Worst Meltdowns
Safe haven stocks offer stability even during market fall in communication, financials, healthcare, energy and consumer staples. 
Via InvestorPlace
Analyst Sentiment, Revenue Growth Will Lead AbbVie Stock Higher
After falling nearly 6% based on concerns about Humira sales, AbbVie stock is recovering, and bullish analyst sentiment is likely to push the stock higher 
Via MarketBeat
Peeling Back The Layers: Exploring AbbVie Through Analyst Insights
Via Benzinga
Will Earnings Cheer Continue To Buoy Markets? Apple, Amazon, Pfizer, Coinbase Lead Flurry Of Q1 Reports This Week
With the earnings season now halfway through, the percentage of S&P 500 companies reporting positive earnings surprises and the magnitude of earnings surprises were above their 10-year averages. 
Via Benzinga
Topics Stocks
Exposures US Equities
AbbVie's Options Frenzy: What You Need to Know
Via Benzinga
Inflation-Proof Fortunes: 7 Dividend Aristocrats to Keep Your Wealth Growing
These dividend aristocrat stocks can protect tired consumers from persistent inflation through dividends that outpace recent spikes. 
Via InvestorPlace
Topics Economy
Exposures Interest Rates
AbbVie Outlook: Why Humira Biosimilars Won't Undo A Projected $73 Billion In Sales
The company is projected to bring in increasing sales through at least 2029. 
Via Investor's Business Daily
Better Dividend Stock: AbbVie or Johnson & Johnson?
One thing is for sure: Dividend seekers can't go wrong with either. 
Via The Motley Fool
3 Dividend Stocks to Buy and Hold for the Next Decade
You'll get dividends and more with these great stocks. 
Via The Motley Fool
Why AbbVie Stock Stumbled Today Despite the Earnings Beat
Investors are struggling to see past the end of Humira's dominance. 
Via The Motley Fool
AbbVie (ABBV) Q1 2024 Earnings Call Transcript
ABBV earnings call for the period ending March 31, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Arthritis Patients - Cigna's Evernorth To Offer Humira Biosimilar At No Out-of-Pocket Cost
Evernorth Health Services' initiative to offer Humira biosimilar with $0 out-of-pocket costs for patients. Save an average of $3,500 yearly. 
Via Benzinga
Tech Stocks Rebound As Magnificent 7 Roar On Strong Earnings, Energy Giants Tumble: What's Driving Markets Friday?
Strong earnings reports from Alphabet Inc. (NASDAQ:GOOGL) and Microsoft Corp. (NASDAQ:MSFT) have restored positive sentiment in the market, sweeping away fears of increasing risks of stagflation that... 
Via Benzinga
Topics Economy
Exposures Interest Rates
ABBV Stock Earnings: AbbVie Beats EPS, Beats Revenue for Q1 2024
ABBV stock results show that AbbVie beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
Ex-Humira Growth Platform Drives AbbVie's Q1 Performance, Drugmaker Lifts Annual Profit Outlook
AbbVie impresses with Q1 results: EPS beats at $2.31 (-6.1% Y/Y), net revenue exceeds at $12.31 billion (+0.7%). Notable: Immunology sales, Humira vs. biosimilars, oncology gains. 
Via Benzinga
AbbVie Beats First-Quarter Views As Skyrizi Looks To Take Humira's Title
Skyrizi brought in $2.01 billion in sales, just barely trailing the $2.27 billion generated by the struggling Humira. 
Via Investor's Business Daily
Wall Street Futures Ride High On Microsoft, Alphabet Cheer, But Will Inflation Data Burst The Bubble? Why This Analyst Thinks Bull Run Isn't Over Yet
Tech earnings could come to the market’s rescue as traders remain jittery about the outcome of key inflation data due on Friday. 
Via Benzinga
Topics Economy
Exposures Interest Rates
AbbVie's Dermatitis Drug Shown 'Superior' To Sanofi/Regeneron's Dupixent In Head-To-Head Study
AbbVie's Upadacitinib outperforms dupilumab in Phase 3b/4 study for atopic dermatitis treatment, achieving superior efficacy and rapid skin clearance than Dupixent. 
Via Benzinga
3 Biotech Stocks That Could Be Multibaggers in the Making: April Edition
Many fortunes have been made with a fortuitous investment in a biotech stock at the right time. That time might be now. 
Via InvestorPlace
Dividend Growth Stars: 7 Stocks With 10-Year Double-Digit Rate Hikes
It's not just enough for a company to pay a dividend, investors should look for dividend growth stocks that can continue to pay. 
Via InvestorPlace
Buying the Dip in These 3 Undervalued Dividend Stocks
All three of these stocks look intriguing. 
Via The Motley Fool
3 Dividend Kings Down 11% You’ll Regret Not Buying on the Dip
These dividend stocks have proved time and again why they're the cream of the crop and will rise to the top once more. 
Via InvestorPlace
Why I Keep Buying This Ultra-High-Yielding ETF for Passive Income
The JPMorgan Equity Premium Income ETF produces a lucrative monthly passive income stream. 
Via The Motley Fool
Topics ETFs
Can Magnificent 7 Help Script Market Turnaround? Earnings Pick Up Pace With Microsoft, Meta, Alphabet And Tesla Expected This Week
Corporate profit growth rose in Q3 2023 and is expected to continue in Q1. 
Via Benzinga
These 3 Small-Cap Stocks Are Up 304% in 2024. Can They Run Higher?
Small-cap stocks have been the market laggards but these standouts showed how to beat even top-tier tech names at their own game. 
Via InvestorPlace
The Bad News Heading Into AbbVie's First-Quarter Earnings Report
AbbVie is working against numerous biosimilar versions of Humira. But one has "stepped up dramatically." 
Via Investor's Business Daily
Soon To Be Acquired Cerevel Therapeutics Reveals High Level Data From Late-Stage Parkinson's Disease Study
Discover toplines results of Cerevel Therapeutics' Phase 3 TEMPO-3 trial for tavapadon in Parkinson's disease treatment. Statistically significant efficacy and safety findings were revealed. 
Via Benzinga
< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
71 72 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 LosAltos.com & California Media Partners, LLC. All rights reserved.